SEGMENTS (Details) - USD ($)	3 Months Ended				6 Months Ended		193 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020
Revenues	$ 7,787,594		$ 6,560,942		$ 17,987,338	$ 10,089,531
Cost of product revenue	13,495,629		10,491,236		30,324,855	19,896,415
Loss from operations	(17,123,825)		(11,338,674)		(33,893,611)	(24,547,090)
Gain on transfer of plasma center assets	0		0		0	11,527,421
Loss on the extinguishment of debt	0		0		0	9,962,495
Net loss	(20,178,091)	$ (19,245,230)	(13,211,872)	$ (13,067,955)	(39,423,321)	(26,279,827)	$ 304,100,000
Depreciation and amortization expense					1,674,490	1,611,422
Consolidated (member)
Revenues	7,787,594		6,560,942		17,987,338	10,089,531
Cost of product revenue	13,495,629		10,491,236		30,324,855	19,896,415
Loss from operations	(17,123,825)		(11,338,674)		(33,893,611)	(24,547,090)
Interest and other expense, net	(3,054,266)		(1,873,198)		(5,529,710)	(3,297,663)
Gain on transfer of plasma center assets	0					11,527,421
Loss on the extinguishment of debt						(9,962,495)
Net loss	(20,178,091)		(13,211,872)		(39,423,321)	(26,279,827)
Capital expenditure	6,243,284				6,243,284	245,675
Depreciation and amortization expense	885,652		806,093		1,674,490	1,611,422
TOTAL ASSETS	191,541,568		143,274,120
Plasma Collection Centers
Revenues	1,249,020		2,522,788		3,669,782	4,671,686
Cost of product revenue	1,258,488		2,320,855		3,635,761	3,785,688
Loss from operations	(919,309)		(392,181)		(1,376,464)	(362,601)
Interest and other expense, net	(33)		(59)		(33)	13,560
Gain on transfer of plasma center assets	0		0			11,527,421
Loss on the extinguishment of debt	0		0
Net loss	(919,342)		(392,240)		(1,376,497)	11,178,380
Capital expenditure					1,178,790	21,235
Depreciation and amortization expense	111,106		113,958		222,395	228,199
TOTAL ASSETS	7,542,486		3,835,999
Corporate
Revenues	35,709		35,709		71,417	71,417
Cost of product revenue	0		0
Loss from operations	(3,351,681)		(2,274,710)		(7,188,167)	(4,891,898)
Interest and other expense, net	(2,818,791)		(1,626,536)		(5,055,363)	(2,895,007)
Gain on transfer of plasma center assets	0		0
Loss on the extinguishment of debt						(9,962,495)
Net loss	(6,170,472)		(3,901,246)		(12,243,530)	(17,749,400)
Capital expenditure	0		0		6,243,284	245,675
Depreciation and amortization expense	2,305		3,287		4,881	6,983
TOTAL ASSETS	74,893,664		72,201,705
ADMA BioManufacturing
Revenues	6,502,865		4,002,445		14,246,139	5,346,428
Cost of product revenue	12,237,141		8,170,381		26,689,094	16,110,727
Loss from operations	(12,852,835)		(8,671,783)		(25,328,980)	(19,292,591)
Interest and other expense, net	(235,442)		(246,603)		(474,314)	(416,216)
Gain on transfer of plasma center assets	0		0
Net loss	(13,088,277)		(8,918,386)		(25,803,294)	(19,708,807)
Capital expenditure					5,064,494	224,440
Depreciation and amortization expense	772,241		688,848		$ 1,447,214	$ 1,376,240
TOTAL ASSETS	$ 109,105,418		$ 67,236,416